Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial

MLA

Lucia Del Mastro, et al. “Abstract P4-14-01: Modulation of Tumor Infiltrating Lymphocytes (TILs) by Palbociclib, Trastuzumab, Pertuzumab +/- Fulvestrant in ER+/HER2+ Patients (Pts) Enrolled in the Michelangelo NA-PHER2 Trial.” Cancer Research, vol. 80, Feb. 2020, pp. P4-14. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs19-p4-14-01.

APA

Lucia Del Mastro, Antonio Frassoldati, Giancarlo Bisagni, Mauro Mansutti, Stefania Zambelli, Marco Colleoni, Claudio Zamagni, Luca Licata, Pinuccia Valagussa, Giuseppe Viale, Chanel Smart, Giampaolo Bianchini, & Luca Gianni. (2020). Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial. Cancer Research, 80, P4-14. https://doi.org/10.1158/1538-7445.sabcs19-p4-14-01

Chicago

Lucia Del Mastro, Antonio Frassoldati, Giancarlo Bisagni, Mauro Mansutti, Stefania Zambelli, Marco Colleoni, Claudio Zamagni, et al. 2020. “Abstract P4-14-01: Modulation of Tumor Infiltrating Lymphocytes (TILs) by Palbociclib, Trastuzumab, Pertuzumab +/- Fulvestrant in ER+/HER2+ Patients (Pts) Enrolled in the Michelangelo NA-PHER2 Trial.” Cancer Research 80 (February): P4-14. doi:10.1158/1538-7445.sabcs19-p4-14-01.